Hypoxic Stress and Inflammatory Pain Disrupt Blood-Brain Barrier Tight Junctions: Implications for Drug Delivery to the Central Nervous System

被引:0
作者
Jeffrey J. Lochhead
Patrick T. Ronaldson
Thomas P. Davis
机构
[1] University of Arizona,Department of Pharmacology
来源
The AAPS Journal | 2017年 / 19卷
关键词
blood-brain barrier; drug delivery; hypoxia; pain; tight junctions;
D O I
暂无
中图分类号
学科分类号
摘要
A functional blood-brain barrier (BBB) is necessary to maintain central nervous system (CNS) homeostasis. Many diseases affecting the CNS, however, alter the functional integrity of the BBB. It has been shown that various diseases and physiological stressors can impact the BBB’s ability to selectively restrict passage of substances from the blood to the brain. Modifications of the BBB’s permeability properties can potentially contribute to the pathophysiology of CNS diseases and result in altered brain delivery of therapeutic agents. Hypoxia and/or inflammation are central components of a number of diseases affecting the CNS. A number of studies indicate hypoxia or inflammatory pain increase BBB paracellular permeability, induce changes in the expression and/or localization of tight junction proteins, and affect CNS drug uptake. In this review, we look at what is currently known with regard to BBB disruption following a hypoxic or inflammatory insult in vivo. Potential mechanisms involved in altering tight junction components at the BBB are also discussed. A more detailed understanding of the mediators involved in changing BBB functional integrity in response to hypoxia or inflammatory pain could potentially lead to new treatments for CNS diseases with hypoxic or inflammatory components. Additionally, greater insight into the mechanisms involved in TJ rearrangement at the BBB may lead to novel strategies to pharmacologically increase delivery of drugs to the CNS.
引用
收藏
页码:910 / 920
页数:10
相关论文
共 450 条
  • [1] Abbott NJ(2013)Blood-brain barrier structure and function and the challenges for CNS drug delivery J Inherit Metab Dis 36 437-449
  • [2] Strazielle N(2013)Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules Mol Pharm 10 1473-1491
  • [3] Ghersi-Egea JF(2011)Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery Ther Deliv 2 1015-1041
  • [4] Ronaldson PT(2012)Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke Curr Pharm Des 18 3624-3644
  • [5] Davis TP(2005)The blood-brain barrier: bottleneck in brain drug development Neuro Rx. 2 3-14
  • [6] Ronaldson PT(1969)Junctions between intimately apposed cell membranes in the vertebrate brain J Cell Biol 40 648-677
  • [7] Davis TP(1990)Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study J Physiol 429 47-62
  • [8] Pardridge WM(1967)Fine structural localization of a blood-brain barrier to exogenous peroxidase J Cell Biol 34 207-217
  • [9] Brightman MW(2009)Characteristics of compounds that cross the blood-brain barrier BMC Neurol 9 S3-1758
  • [10] Reese TS(2007)Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development Pharm Res 24 1745-673